Skin Conditions
Also known as: Cutaneous disorders, Dermatologic disorders, Skin, Dermis, Cutis
Methodology & AI Transparency ⓘ
Skin Conditions Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What does your skin do? Your skin is your body's largest organ.
- 2 Real-world patient consensus: Mapped to Dermatology: Acne, Eczema, Psoriasis & Rosacea under ICD-10-CM L98.9 for Skin Conditions clinical workups.
- 3 Typical cash cost range: Primary evaluation for Skin Conditions incorporates contact/systemic trigger review [Skin Conditions L98.9] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Skin Conditions monitoring tracks Fasting Lipids & in Skin Conditions (L98.9: ALT (if systemic) toward Within baseline reference limits (L98.9).
Ask our AI Specialists anything about Skin Conditions
What Is Skin Conditions?
What does your skin do? Your skin is your body's largest organ. It covers the entire outside of your body. There are many ways that your skin protects your body and helps keep you healthy. For example, it: Holds body fluids in, which helps prevent you from getting dehydrated Keeps out harmful germs, which helps prevent infections Helps you feel things like heat, cold, and pain Helps control your body temperature Makes vitamin D when the sun shines on it Shields your body against heat and light What problems and conditions can affect your skin? There are many different problems and conditions which can affect your skin.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Skin Conditions (L98.9) center on or pilosebaceous follicular in Skin Conditions (L98.9: hyperkeratinization). Cross-referenced with NIH MeSH (Skin Diseases), targeted skin & dermatology interventions aim to normalize Fasting Lipids & in Skin Conditions (L98.9: ALT (if systemic).
Common Symptoms & Clinical Signs
- • Holds body fluids in, which helps prevent you from getting dehydrated
- • Keeps out harmful germs, which helps prevent infections
- • Presentation of Skin Conditions (L98.9): post-inflammatory hyperpigmentation, facial in Skin Conditions (L98.9: flushing, or pitted)
- • Secondary Skin Conditions clinical sign: recurrent flares triggered in Skin Conditions (L98.9: by UV exposure,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Skin Conditions Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L98.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Skin Conditions (L98.9: ALT (if systemic) | Within baseline reference limits (L98.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Skin Conditions (L98.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (L98.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Skin Conditions (L98.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L98.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Skin Conditions
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Hydroquinone Olivia Quido Blemish Eraser, Obagi-C Rx System C-Therapy Night • RxCUI 197795 | Melanin Synthesis Inhibitor | 79% | $0.4445 | $ 26.50 /mo |
| Methazolamide Neptazane • RxCUI 197939 | Eye Health Agent | 90% | $0.6275 | $ 17.08 /mo |
| Manganum Metallicum (Manganese) Manganum Metallicum • RxCUI RXN-B02203300 | Paramagnetic Contrast Agent | 88% | $2.6500 | $ 199.30 /mo |
| Glycopyrrolate Oral Solution Glycopyrrolate Oral Solution Generic • RxCUI 999961 | Anticholinergic | 90% | $0.1689 | $ 15.34 /mo |
| Potassium Citrate and Citric Acid Monohydrate Potassium Citrate and Citric Acid Monohydrate Generic • RxCUI 309318 | Anti-coagulant | 86% | $0.0414 | $ 10.18 /mo |
| Fluorometholone Acetate Flarex • RxCUI 1249629 | Corticosteroid | 78% | $23.9177 | $ 185.00 /mo |
| Carisoprodol Soma • RxCUI 197446 | Muscle Relaxant | 82% | $0.3644 | $ 23.26 /mo |
| Phenobarbital Sodium Sezaby • RxCUI 198368 | FDA Prescription Therapeutic Agent | 78% | $0.2168 | $ 17.28 /mo |
| Sodium Citrate and Citric Acid Sodium Citrate and Citric Acid Generic • RxCUI 543014 | Calculi Dissolution Agent | 82% | $0.0229 | $ 9.43 /mo |
| Spironolactone and Hydrochlorothiazide Spironolactone and Hydrochlorothiazide Generic • RxCUI 198224 | Aldosterone Antagonist | 89% | $0.4833 | $ 28.07 /mo |
| Papaverine Hydrochloride Papaverine Hydrochloride Generic • RxCUI 1789947 | FDA Prescription Therapeutic Agent | 74% | $0.1900 | $ 16.20 /mo |
| Tricitrates Tricitrates Generic • RxCUI 309317 | Anti-coagulant | 74% | $0.0298 | $ 9.71 /mo |
| Promethazine Hci Promethazine Hci Generic • RxCUI 992858 | Phenothiazine | 87% | $2.0262 | $ 90.56 /mo |
| Calcitonin Salmon Miacalcin • RxCUI 308866 | Calcitonin | 85% | $11.1405 | $ 185.00 /mo |
| Prednisone Deltasone • RxCUI 312617 | Corticosteroid | 88% | $0.0638 | $ 5.68 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Skin Conditions)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients: What a 1,614-Participant Study Found Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne. The Journal of dermatological treatment • 2023-12-15 • Randomized Controlled Trial | N = 1,614 | 96/100 | PMID 36382987 ↗ |
| New Insights on Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy: What a 1,564-Participant Study Found The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. BMC infectious diseases • 2024-12-30 • Phase III Randomized Trial | N = 1,564 | 96/100 | PMID 39736611 ↗ |
| New Insights on Incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic: What a 259-Participant Study Found The incidence of TD was relatively low in both younger and older patients with depression with psychotic features treated acutely with olanzapine. Journal of clinical psychopharmacology • 2013-06-15 • Randomized Controlled Trial | N = 259 | 93/100 | PMID 23609383 ↗ |
| New Insights on Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute: What a 335-Participant Study Found TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-10-05 • Phase III Randomized Trial | N = 335 | 93/100 | PMID 32897367 ↗ |
| New Insights on Secukinumab maintains superiority over ustekinumab in clearing skin and improving: What a 550-Participant Study Found This second head-to-head study confirmed the superior efficacy of secukinumab over ustekinumab in skin clearance and quality of life through 52 weeks, with safety comparable to that reported in previous trials. Journal of the European Academy of Dermatology and Venereology : JEADV • 2021-01-15 • Phase III Randomized Trial | N = 550 | 93/100 | PMID 32365251 ↗ |
Skin Conditions Patient Community & “People Like Me” Threads
Filter Skin Conditions community threads and patient logs by age, biological sex, dosage, and treatment duration.